 Connection
Danica Wiredja to Humans
This is a "connection" page, showing publications Danica Wiredja has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.129 |
|
|
|
-
Wiredja D, Libert D, Jangam D, Ho C, Tung J, Zhang BM. Performance Evaluation of a Next-Generation Sequencing-Based T-Cell Receptor Gene Rearrangement Assay. J Mol Diagn. 2025 Jun; 27(6):465-474.
Score: 0.022
-
Wiredja D, Ritchie TA, Tam G, Hogan CA, Pinsky B, Shi RZ. Performance evaluation and optimized reporting workflow for HIV diagnostic screening and confirmatory tests in a low prevalence setting. J Clin Virol. 2021 12; 145:105020.
Score: 0.017
-
Wiredja DD, Tabler CO, Schlatzer DM, Li M, Chance MR, Tilton JC. Global phosphoproteomics of CCR5-tropic HIV-1 signaling reveals reprogramming of cellular protein production pathways and identifies p70-S6K1 and MK2 as HIV-responsive kinases required for optimal infection of CD4+ T cells. Retrovirology. 2018 07 03; 15(1):44.
Score: 0.014
-
Wiredja DD, Ayati M, Mazhar S, Sangodkar J, Maxwell S, Schlatzer D, Narla G, Koyutürk M, Chance MR. Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator. Proteomics. 2017 Nov; 17(22).
Score: 0.013
-
Wiredja D, Bebek G. Identifying Gene Interaction Networks. Methods Mol Biol. 2017; 1666:539-556.
Score: 0.012
-
Gray MT, Cayrol R, May A, Skaugen JM, Hayek F, Lapointe S, Hawkins CE, Pearce TM, Pratt D, Wiredja D, Toland A, Marker DF. Gliomas with succinate dehydrogenase deficiency: A case series and brief review of the literature of oncometabolite-driven gliomagenesis. J Neuropathol Exp Neurol. 2026 Jul 01; 85(7):789-796.
Score: 0.006
-
Corey Z, Wiredja D, Willard N, Wisell J, Raghavan SS. Spitz Nevi With Novel BRAF Fusions: A Report of Two Cases With Striking Morphologic Features. Am J Dermatopathol. 2026 May 01; 48(5):397-401.
Score: 0.006
-
Yasin I, Stengel A, Shao H, Kaur A, Mason EF, Patwardhan PP, Bailey NG, Ghosh S, Inamdar KV, Patel AA, Pandiri M, Zhang J, Sojitra P, Tariq H, Pan Z, Wiredja D, Wang P, Tjota MY, Segal JP, Chang H, Sallman DA, Arber DA, Tefferi A, Badar T, Perry AM, Haferlach C, Lager AM, Venkataraman G. Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
Score: 0.006
-
Pandiri M, Stengel A, Zhang J, Wang P, Shao H, Velmurugan S, Jacob A, Symes E, Kaur A, Rojek A, Sojitra P, Wiredja D, Zhou Q, Chang H, Patil E, Patel JL, Patel AB, Menon M, Ghosh S, Wool GD, Arber DA, Pan Z, Findley A, Badar T, Tariq H, Sallman D, Bell RC, Perry A, Haferlach C, Fitzpatrick C, Venkataraman G. Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
Score: 0.006
-
Pepper MA, Wiredja DD, Patel PM, Stevens BA, Pinsky BA, Shi RZ. A spurious positive result on the Abbott Architect 4th generation HIV Ag/Ab combo assay in a low-risk patient. Clin Chim Acta. 2022 06 01; 531:386-388.
Score: 0.005
-
Wang H, Wiredja D, Yang L, Bulterys PL, Costales C, Röltgen K, Manalac J, Yee J, Zehnder J, Shi RZ, Boyd SD, Pinsky BA. Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results. Clin Chem. 2021 07 06; 67(7):977-986.
Score: 0.004
-
Leonard D, Huang W, Izadmehr S, O'Connor CM, Wiredja DD, Wang Z, Zaware N, Chen Y, Schlatzer DM, Kiselar J, Vasireddi N, Schüchner S, Perl AL, Galsky MD, Xu W, Brautigan DL, Ogris E, Taylor DJ, Narla G. Selective PP2A Enhancement through Biased Heterotrimer Stabilization. Cell. 2020 04 30; 181(3):688-701.e16.
Score: 0.004
-
O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G. Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene. 2020 01; 39(3):703-717.
Score: 0.004
-
Ayati M, Wiredja D, Schlatzer D, Maxwell S, Li M, Koyutürk M, Chance MR. CoPhosK: A method for comprehensive kinase substrate annotation using co-phosphorylation analysis. PLoS Comput Biol. 2019 02; 15(2):e1006678.
Score: 0.004
-
McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD. Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Res. 2018 04 15; 78(8):2065-2080.
Score: 0.003
-
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest. 2017 Jun 01; 127(6):2081-2090.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|